HPV: General, prevention and vaccination
DOI:
https://doi.org/10.19230/jonnpr.3767Keywords:
Human papilloma virus, infection, cervical cancer, preventionAbstract
Aim. To document the generalities, prevention and treatment of human papillomavirus infection.
Material and methods. Relevant information was collected, original research articles, clinical trials, and reviews in indexed journals, to know the generalities of the human papilloma virus, pro HPV infections and cervical cancer and what are the prevention measures.
Results. Human papillomavirus or papillomavirus are a group of DNA viruses that belong to the Papillomaviridae family, without envelopes, and have a diameter of 52-55 nm. Viral particles are composed of a protein capsid, made up of 95% by the L1 protein and 5% by the L2 protein, which are assembled to form icosahedral capsomeres.
Conclusions. The importance of vaccination resides in the primary prevention that is carried out against HPV infections, however, this action goes beyond just preventing infection, it is avoiding an injury that is a precursor to CACU. The introduction of the HPV vaccine into the Mexican vaccination scheme, not only impacts on the prevention of CACU and HPV infection, it also supposes the protection of the pocket of the families, which in this way would avoid a catastrophic expense for CACU. This would mean non-positive results.
Downloads
References
Secretaría de Salud. Defunciones cifras oficiales definitivas. [Internet]. 2019. Available from: http://sinba08.salud.gob.mx/cubos/cmortalidadxp.html
Uterino C. Boletín. 2018;
Salva- E. Panorama epidemiológico del cáncer cervicouterino. 2015;
Cabrera P, Motola-kuba D, Sur HM, Rivera-rivera S, Cardenas E. Mortalidad por Cáncer en México: actualización 2015. 2018;(April).
Tirado-gómez LL, C M, Mohar-betancourt A, López-cervantes M, García-carrancá A. Factores de riesgo de cáncer cervicouterino invasor en mujeres mexicanas. 2005;47(5).
Hild-Mosley KA, Patel DM, Markwell S, Massad SL. Conocimiento de la detección del cáncer de cuello uterino, el virus del papiloma humano y la vacuna contra el VPH entre pacientes de ginecología del Medio Oeste. J Low Genit Tract Dis. 2009;2:146–53.
Organización Mundial de la Salud. Estrategias de vacunación contra el virus del papiloma humano en el mundo en desarollo. Cerv Cancer Action [Internet]. 2007; Available from: http://www.rho.org/files/CCA_estrategias_de_vacunacion_VPH.pdf
Premoli G, González A, Villarreal J, Percoco T, Pietrocino P, Aguilera L. Virus del papiloma humano; visión actual en biomedicina. Rev ADM MG Revisión Revisión Revisión Revisión Revisión. 2005;LXII(6):213–24.
Santos López G, Márquez Rodríguez L, Reyes Leyva J, Vallejo Ruiz V. Aspectos generales de la estructura, clasificación y replicación del virus del papiloma humano. Rev medica Inst Mex del seguro Soc. 2015;53:166.171.
De la Fuente Villarreal D, Guzmán López S, Barboza Quintana O, Gónzalez Ramírez A. Biologíadel Virus del Papiloma Humano y técnica de diagnóstico. Med Univ [Internet]. 2010;12(49):231–8. Available from: www.elsevier.es/en/node/2090153
Castellsagué X, San Martín M, Cortés J, González A, Remy V. Impacto de la vacuna tetravalente frente al virus del papiloma humano (VPH) tipos 6, 11, 16 y 18 en las enfermedades asociadas al VPH en España. Progresos en Obstet y Ginecol [Internet]. 2008;51(9):520–30. Available from: http://dx.doi.org/10.1016/S0304-5013(08)72326-4
Lizano Soberón M, Carrillo Garcia A, Contreras Paredes A. Infección por Virus del Papiloma Humano: Epidemiología, Historia Natural y Carcinogénesis. Inst Nac Cancerol [Internet]. 2009;4:205–16. Available from: http://www.incan.org.mx/revistaincan/elementod/documentosPortada/1272302572.pdf
Schlecht NF, Kulaga S, Robitaille J, Ferreira S, Santos M, Miyamura RA, et al. Persistent human papillomavirus infection as a predictor of cervical intraepithelial neoplasia. J Am Med Assoc. 2001;286(24):3106–14.
Woodman CBJ, Collins SI, Young LS. The natural history of cervical HPV infection: Unresolved issues. Nat Rev Cancer. 2007;7(1):11–22.
Vignolo J, Vecarezza M, ÁLvarez C, Sosa A. Levels of care, prevention and primary health care. Arch Med Interna. 2011;XXXIII(1):11–4.
Organización Mundial de la Salud. Vacunas [Internet]. [cited 2020 Mar 9]. Available from: https://www.who.int/topics/vaccines/es/
Häbich D. Vacuna bivalente contra el VPH. In: Tatti S, Fleider L, Tinnirello M de los Á, Caruso R, editors. Enfoque integral de las patologías relacioandas con el virus del papiloma humano. 1st ed. Buenos Aires: 2017; 2017. p. 195–8.
Acuña Rojas K, Vega Quesada M, Salazar Arias N, Escalante Gómez C. Vacuna contra virus del Papiloma Humano: Análisis de esquemas de dos dosificaciones. Rev Clínica Esc Med UCR-HSJD. 2016;6(3):11–22.
Marès Bermúdez J. Vacunación frente al virus del papiloma humano y adolescencia. Pediatr Integr. 2015;19(10):693.e-693.e.
Fleider L. Vacuna tetravalente contra el HPV. In: Tatti S, Fleider L, Tinnirello M de los Á, Caruso R, editors. Enfoque integral de las patologías relacioandas con el virus del papiloma humano. 1st ed. Buenos Aires: 2017; 2017. p. 199–205.
Tatti S. Vacuna nonavalente contra el HPV. In: Tatti S, Fleider L, Tinnirello M de los Á, Caruso R, editors. Enfoque integral de las patologías relacioandas con el virus del papiloma humano. 1st ed. Buenos Aires: 2017; 2017. p. 207–11.
Varela Martínez S. Citología cervical. Ginecol Obstet Mex. 2005;73(3):131–6.
Aue-Aungkul A, Suprasert P. Reid colposcopic index evaluation: Comparison of general and oncologic gynecologists. Asian Pacific J Cancer Prev. 2015;16(12):5001–4.
Pérez Montiel D, Alvarado Cabrero I, Chablé Montero F, Arrazola González J, Vilches Cisneros N, Barrón Rodríguez L, et al. Patología del cáncer cervicouterino. Gac Mex Oncol. 2014;13(4):33–8.
Published
Issue
Section
License
All accepted originals remain the property of JONNPR. In the event of publication, the authors exclusively transfer their rights of reproduction, distribution, translation and public communication (by any sound, audiovisual or electronic medium or format) of their work. To do so, the authors shall sign a letter transferring these rights when sending the paper via the online manuscript management system.
The articles published in the journal are freely used under the terms of the Creative Commons BY NC SA license, therefore.
You are free to:
Share — copy and redistribute the material in any medium or format
Adapt — remix, transform, and build upon the material
The licensor cannot revoke these freedoms as long as you follow the license terms.
Under the following terms:
Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
NonCommercial — You may not use the material for commercial purposes.
ShareAlike — If you remix, transform, or build upon the material, you must distribute your contributions under the same license as the original.
No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License
